Venous thromboembolism risk and prophylaxis in the acute hospital care setting-results of the Endorse study in Tunisia

##plugins.themes.academic_pro.article.sidebar##

Published Nov 10, 2011
Download
pdf
Vol. 89 No. 10 (2011): Issue Oct 2011

##plugins.themes.academic_pro.article.main##

Zouheir Jerbi
Mohamed H. Houman
Habib Ghedira
Samir Kamoun
Afif Ben Salah

Abstract

Background : There are not information about the risk of venous thromboembolism (VTE) and its prophylaxis in Tunisia.
Aim: To report the Tunisian results of a multinational crosssectional study, designed to assess the prevalence of VTE risk in the acute hospital care setting and to determine the proportion of at risk patients who receive effective prophylaxis.
Methods: All hospital inpatients aged 40 years or over admitted to a medical ward or these aged 18 years or over admitted to surgical ward, in 5 Tunisian hospitals were assessed for risk of VTE on the basis of hospital chart review. The 2004 American College of chest physicians (ACCP) evidence based consensus guidelines were used to assess VTE risk and to determine whether patients were received recommended prophylaxis.
Results: 885 were enrolled, 212 (24%) were surgical and 673 (76%) were medical. 408 (44, 9%) judged to be at risk, 95 (44, 8%) are surgical and 313 (46, 5%) are medical. LWMH are the most used. Mechanical prophylaxis was never used.
Conclusion: The percentage of at risk patient in Tunisia is comparable to these of other countries. The majority of at risk patient are medical. The prophylaxis was under used. Hospital strategies to assess patient VTE risk and implementation of prophylaxis protocols are needed.

Keywords:

Venous Thromboembolism; Risk; Prophylaxis

##plugins.themes.academic_pro.article.details##

References

  1. Cohen A T, Topson V F, Bergman J F, et al for the Endorse Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (Endorse study): a multinational cross-sectional study. Lancet 2008; 371: 387-94
  2. Geerts W H, Pineo G F, Heit J A, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 suppl): 338S-400S.
  3. Linblad B, Sternbay NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302: 709-11.
  4. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82:203-05.
  5. Alikhan R, Peters F, Wilnott R, Choen AT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol 2004; 57:1254-57.
  6. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82:423-28.
  7. Pengo V, Lensing AW, Prins MH, et al. Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350:2257-64.
  8. Clagett GP, Anderson Jr FA, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism. Chest 1992; 102 (4 suppl): 391S-407S.
  9. Otero R, Uresandi F, Cayuela A, et al. Use of venous thromboembolism prophylaxis for surgical patients: a multicentre analysis of practice in Spain. Eur J Surg 2001;167:163-67.
  10. Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals'compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm. 2007; 64:69-76.
  11. Eikelboom JW, Mazzarol A, Quinlan DJ, et al: The American College of Chest Physicians. Thromboprophylaxis practice patterns in two Western Australian teaching hospitals. Haematologica 2004; 89:586-93.
  12. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost 2007; 5:1610-16.
  13. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registery on venous thromboembolism. Chest 2007; 132:936-45.
  14. Kakkar VV, Corrigan TP, Fossard DP, Sutherland I, Shelton MG, Thirlwall J. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an international multicentre trial. Lancet 1975:306; 45-51.
  15. Baglin T, Barrowcliffe TW, Cohen A, Greaves M; British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin. Br J Haematol 2006; 133:19-34.
  16. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94:750-59.
  17. Kahn SR, Panju A, Geerts W. et al. Multicenter evaluation of the use of venous thromboembolism in acutely ill medical patients in Canda. Throm Res 2007; 119:145-55.
  18. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 199; 341:793-800.
  19. Cohen AT, Davidson BL, Gallus AS, et al: ARTEMIS Investigators; Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 2006; 332:325-29.
  20. Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D. Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82:777- 82.
  21. Cohen AT, Agnelli G, Anderson FA Jr, et al. Venous thromboembolism in Europe: the number of VTE events and associated